Pasar al contenido principal

FUNCION, ESTRUCTURA Y DISEÑO DE SENSORES MOLECULARES QUE CONTROLAN LA RESPUESTA DE LAS PLANTAS AL ESTRES POR SEQUIA Y SAL

PID2020-119805RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Development of pharmacological tools to study the kv4.3 channelosome in atrial fibrillation

  • Viedma, Carmen
  • Sandin, P.
  • Bonache de Marcos, María Ángeles
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado en el XX National Meeting of the Spanish Society of Medicinal Chemistry, celebrado en Santiago de Compostela (España) del 19 al 22 de junio de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions, such as smooth muscle contraction or secretion of hormones. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3 and its role in atrial fibrillation (AF). KV4.3 channel is expressed in smooth muscle, heart and brain. Its activation generates outward currents operating at subthreshold membrane potentials as recorded from myocardial cells (ITO, transient outward current). KV4.3 plays a key role in AF, the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] To reproduce the ITO currents, KV4.3 channels need to assemble with other subunits, forming channelosome. KChIPs (Potassium Channel Interacting Proteins), which belong to the calcium binding protein superfamily, forms the KV4.3 channelosome, along with other proteins.[3] To study the complex interaction of KV4.3 channelosome and the development of modulators, the interplay of different techniques is central to advance knowledge. In this regard, the development of novel KChIPs modulators and fluorescent biosensors constitutes invaluable pharmacological tools to unravel the KV4 channelosome and its role in AF.[3] In this communication, we will describe preliminary results towards the identification of new pharmacological tools to study the KChIPs/KV4 interaction., This work was supported by the projects: PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 funded by MCIN/ AEI /10.13039/501100011033; and the projects PIE202180E073 and 2019AEP148 funded by CSIC. C. Viedma Barba holds the grant PRE2020-093542 and M. Valencia holds the grant PRE2020-093950, both funded by MCIN/AEI/10.13039/501100011033. A. Pérez-Lara holds the grant RYC2018-023837-I funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

New approaches for the identification of KChIP2 ligands to study the KV4.3 channelosome in atrial fibrillati

  • Viedma, Carmen
  • Martinez-Salas, P.
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Marín-Olivero, Irene
  • Daniel-Mozo, Miguel
  • Pérez-Lara, Ángel
  • González-Vera, Juan A.
  • Orte, Angel
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado en el VIII Congreso Red Española de Canales iónico, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3. Kv4.3 is expressed in smooth muscle, heart and brain. Within the heart, Kv4.3 channels generate the transient outward potassium current (ITO). However, ITO characteristics are only observed when Kv4.3 assemble with accessory subunits as KChIP2 and DPP6. KV4.3 channelosome play a key role in atrial fibrillation (AF),the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] KChIP2 (Potassium Channel Interacting Protein 2) belongs to the calcium binding protein superfamily. It is the KChIP member predominantly expressed in heart and a key regulator of cardiac action potential duration. The identification of novel KChIP2 ligands could be useful to understand the role of KV4.3 channelosome in AF and it could help to discover new treatments for AF. [3] In this regard, structure-based virtual screening could be an important tool to accelerate the identification of novel KChIP2 ligands. In this communication, we will describe a multidisciplinary approach that, starting with a structurebased virtual screening, followed by an iterative process of synthesis/biological evaluation/docking studies, has led to the identification of new KChIP2 ligands., PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; and PIE202180E073 and 2019AEP148 funded by CSIC. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033. PGS was recipient of an FPU grant (FPU17/02731). AB-B holds BES-2017-080184 FPI grant and A.P-L.holds RYC2018-023837-I grant both funded by MCIN/ AEI/ 10.13039/501100011033 and by “ESF Investing in your future”
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

New approaches for the identification of KChIP2 ligands to study the KV4.3 channelosome in atrial fibrillati

  • Viedma, Carmen
  • Martinez-Salas, P.
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Marín-Olivero, Irene
  • Daniel-Mozo, Miguel
  • Pérez-Lara, Ángel
  • González-Vera, Juan A.
  • Orte, Angel
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado en el VIII Congreso Red Española de Canales iónico, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3. Kv4.3 is expressed in smooth muscle, heart and brain. Within the heart, Kv4.3 channels generate the transient outward potassium current (ITO). However, ITO characteristics are only observed when Kv4.3 assemble with accessory subunits as KChIP2 and DPP6. KV4.3 channelosome play a key role in atrial fibrillation (AF),the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] KChIP2 (Potassium Channel Interacting Protein 2) belongs to the calcium binding protein superfamily. It is the KChIP member predominantly expressed in heart and a key regulator of cardiac action potential duration. The identification of novel KChIP2 ligands could be useful to understand the role of KV4.3 channelosome in AF and it could help to discover new treatments for AF. [3] In this regard, structure-based virtual screening could be an important tool to accelerate the identification of novel KChIP2 ligands. In this communication, we will describe a multidisciplinary approach that, starting with a structurebased virtual screening, followed by an iterative process of synthesis/biological evaluation/docking studies, has led to the identification of new KChIP2 ligands., PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; and PIE202180E073 and 2019AEP148 funded by CSIC. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033. PGS was recipient of an FPU grant (FPU17/02731). AB-B holds BES-2017-080184 FPI grant and A.P-L.holds RYC2018-023837-I grant both funded by MCIN/ AEI/ 10.13039/501100011033 and by “ESF Investing in your future”
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

IQM-110, a new selective inhibitor of KChIP and its pharmacological effects on Kv4., Kv4./KChIP and Kv4./KChIP currents

  • Benito-Bueno, Ángela de
  • Bonache de Marcos, María Ángeles
  • Viedma, Carmen
  • Martín-Martínez, Mercedes
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Trabajo presentado en el VIII Congreso Red Española de Canales iónicos, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., Kv4 channels generate outward currents activated at subthreshold membrane potentials and are responsible for the repolarization of both cardiac and neuronal action potentials through ITO (transient outward current) and IA (A-type K+ current), respectively. Kv4 dysfunctions have been identified in cardiac diseases (i.e. Brugada syndrome or atrial fibrillation) as well as in neuronal diseases (i.e. schizophrenia, epilepsy or Alzheimer’s disease). However, Kv4 channels need to assemble with regulatory or β subunits to fully reproduce ITO and IA currents. Among them, we will focus on KChIPs (potassium channel interacting proteins), being KChIP3 predominant in the brain and KChIP2 in both brain and heart. The assembly of these β subunits alters not only the biophysical properties of the channel, but also its pharmacology. For this reason, we have analysed the electrophysiological effects of IQM-22110 (a new compound designed to bind KChIP3) on the currents generated by Kv4.3, Kv4.3/KChIP2 and Kv4.3/KChIP3 channels. CHO cells were transiently transfected (Kv4.3, Kv4.3/KChIP2 or Kv4.3/KChIP3), and the potassium currents were recorded using the whole-cell patch-clamp technique. Our results indicate that IQM-22110 exerts differential effects on Kv4.3, Kv4.3/KChIP2 and Kv4.3/KChIP3 currents. First of all, the concentration-dependence of inhibition was modified, being the IC50 = 5.5 μM for Kv4.3 channels, 10.4 μM for Kv4.3/KChIP2 and exhibited a biphasic curve when KChIP3 is present (IC50(1) = 0.03 μM and IC50(2) = 26.3 μM), suggesting two binding sites for IQM-22110 in this complex. With molecular dynamics and sitedirected mutagenesis, we have identified two aminoacids (Y130 and K166) in KChIP3 critical to the binding of IQM-22110 to its high affinity site. Also, we selected equipotent concentrations of IQM22110 to further study the biophysical effects of this compound on each situation, demonstrating that IQM-22110 binds to the closed-active state of the channel. In this study we concluded that: i) at low concentrations, IQM-22110 is a selective inhibitor of Kv4.3/KChIP3, ii) Y130 and K166 in KChIP3 are critical to the binding of IQM-22110 to the high affinity site in Kv4.3/KChIP3, and iii) IQM-22110 binds to the closed-active state of Kv4.3, Kv4.3/KChIP2 and Kv4.3/KChIP3., Funded by SAF2016-75021-R; PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; PIE201820E104, CSIC2019AEP148, PIE202180E073 and 2019AEP148 funded by CSIC; CIBER CB/11/00222. PGS holds an FPU grant (FPU17/02731) funded by Ministerio de Universidades. AB-B holds BES-2017-080184 FPI grant funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Study of kv4.3 channelosome: novel kchip2 ligands as pharmacological tools

  • Martinez-Salas, P.
  • Viedma, Carmen
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Daniel-Mozo, Miguel
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Trabajo presentado en el VIII Symposia of medicinal chemistry young researchers, celebrado en Barcelona (España) el 22 de julio de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3. Within the heart, KV4.3 channels generate the transient outward potassium current (ITO). However, ITO characteristics are only observed when KV4.3 assembles with accessory subunits as KChIP2 and DPP6. KV4.3 channelosome play a key role in atrial fibrillation (AF), the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] KChIP2 (Potassium Channel Interacting Protein 2) belongs to the calcium binding protein superfamily. It is the KChIP member predominantly expressed in heart and a key regulator of cardiac action potential duration. Novel KChIP2 ligands could be a useful pharmacological tool to understand the role of KV4.3 channelosome in AF and it could help to discover new treatments for AF. [3] In this communication, we will describe a multidisciplinary approach that, starting with a structure-based virtual screening, followed by an iterative process of synthesis/biological evaluation/docking studies, has led to the identification of new KChIP2 ligands., PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; and PIE202180E073 and 2019AEP148 funded by CSIC. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033. PGS was recipient of an FPU grant (FPU17/02731). AB-B holds BES-2017-080184 FPI grant and A.P-L.holds RYC2018-023837-I grant both funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”.